RG
VERV

Redmile Group’s Verve Therapeutics VERV Stock Holding History

Redmile Group’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-740,261
Closed -$8.31M – 47
2025
Q2 		$8.31M Sell
740,261
-466,903
-39% -$2.66M 0.88% 26
2025
Q1 		$5.52M Sell
1,207,164
-111,000
-8% -$744K 0.52% 36
2024
Q4 		$7.43M Sell
1,318,164
-65,202
-5% -$368K 0.52% 39
2024
Q3 		$6.7M Sell
1,383,366
-80,040
-5% -$465K 0.39% 43
2024
Q2 		$7.14M Sell
1,463,406
-141,109
-9% -$887K 0.43% 44
2024
Q1 		$21.3M Sell
1,604,515
-114,154
-7% -$1.51M 0.78% 40
2023
Q4 		$24M Buy
1,718,669
+908,892
+112% +$11.3M 0.86% 35
2023
Q3 		$10.7M Sell
809,777
-252,183
-24% -$4.06M 0.51% 42
2023
Q2 		$19.9M Sell
1,061,960
-58,719
-5% -$978K 0.76% 38
2023
Q1 		$16.2M Sell
1,120,679
-101,224
-8% -$1.98M 0.7% 46
2022
Q4 		$23.6M Sell
1,221,903
-283,223
-19% -$7.5M 0.97% 31
2022
Q3 		$51.7M Sell
1,505,126
-328,421
-18% -$10.5M 2.01% 17
2022
Q2 		$28M Sell
1,833,547
-1,781
-0.1% -$27.6K 1.07% 26
2022
Q1 		$41.9M Buy
1,835,328
+126,792
+7% +$3.62M 1.31% 23
2021
Q4 		$63M Sell
1,708,536
-160,494
-9% -$6.74M 1.43% 17
2021
Q3 		$87.8M Sell
1,869,030
-67,500
-3% -$3.97M 1.53% 23
2021
Q2 		$117M Buy
+1,936,530
New +$80.4M 1.73% 18

Other funds holding VERV

GCM
Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Redmile Group's VERV Position: Q3 2025 in Review

Redmile Group sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 740,261 shares — an estimated $8.31M sold.

Redmile Group first reported a position in VERV in Q2 2021 and held it in 17 quarters. The position peaked at $117M in Q2 2021. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • Redmile Group reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Redmile Group sold 740,261 Verve Therapeutics shares in Q3 2025, an estimated $8.31M.
  • Redmile Group first reported a position in Verve Therapeutics in Q2 2021 and held it in 17 quarters.
  • Redmile Group's Verve Therapeutics position peaked at $117M in Q2 2021.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on Redmile Group's 13F filing for Q3 2025, filed 14 Nov 2025.